Vincerx Pharma, Inc. (VINC)
After hours:
| Previous close | 0.6903 |
| Open | 0.6885 |
| Bid | 0.5877 x 100 |
| Ask | 0.6361 x 200 |
| Day's range | 0.6100 - 0.6895 |
| 52-week range | 0.6100 - 9.3720 |
| Volume | |
| Avg. volume | 921,533 |
| Market cap | 18.636M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.
- Benzinga
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024. VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options. Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule: The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT)
- GuruFocus.com
Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look
Comparing Vincerx Pharma's Performance Against Analyst Estimates
